Law360, New York (February 09, 2012, 3:59 PM ET) -- Federal lawmakers on Thursday hyped a newly authored piece of legislation that aims to speed up the regulatory approval process for generic pharmaceuticals by requiring drugmakers to fund the U.S. Food and Drug Administration's review process.
Proponents of the Generic Drug and Biosimilars User Fee Act, introduced Wednesday to the U.S. House of Representatives, said the bill mandating that generic pharmaceutical manufacturers put up funding to enable the FDA to handle its backlog of generic new drug applications and streamline the approval process is a boon...
Drug Cos. To Fund FDA Generics Reviews Under New Bill
To view the full article, take a free trial now.
